Abstract
Alzheimer’s disease (AD) was first described and diagnosed by Dr. Alois Alzheimer in 1906 (Hippius and Neundorfer, Dialogues Clin Neurosc 5:101–108, 2003). According to World Health Organization (WHO), AD is the most common cause of dementia, accounting for as many as 60–70% of senile dementia cases and affecting 47.5 million people worldwide (data from 2015) (Dementia Fact Sheet No 362. http://who.int/mediacentre/factsheets/fs362/en/). The median survival time after the onset of dementia ranges from 3.3 to 11.7 years (Todd et al. Int J Geriatr Psychiatry 28:1109–1124, 2013). AD is characterized as a severe, chronic, incurable, and progressive neurodegenerative disorder, associated with memory loss and cognition impairment accompanied by abnormal behavior and personality changes (Godyn et al. Pharmacol Rep 68:127–138, 2016). AD is characterized by neuronal death, which usually correlates with the appearance of key neuropathological changes, including acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of β-amyloid (Aβ plaques), intracellular neurofibrillary tangles by hyperphosphorylated tau protein deposits, neuroinflammation, and widespread neuronal loss (Godyn et al. Pharmacol Rep 68:127–138, 2016; Graham et al. Annu Rev. Med 68:413–430, 2017). The discovery of the degeneration of cholinergic neurons and the reduction of acetylcholine levels in postmortem studies of patients resulted in the use of drugs that leads to the increase of acetylcholine levels in brain (Dubois et al. Lacet Neurol 13:614–629, 2014). At present there is no preventative or curative treatment that interferes with the development of the disease. However, in recent years progress was made in the development of cholinergic drugs which have a positive effect on disease progression. Nowadays, specific drugs that can inhibit the enzyme that degrades acetylcholine are used. The development of new effective drugs involves a difficult and time-consuming process, accompanied by a very high failure rate. In the absence of effective therapies, the estimated number of people with dementia will reach 115 to 131, five million by 2050 (Dubois et al. Lacet Neurol 13:614–629, 2014; Cummings et al. Alzheimers Res Ther 6:37, 2014). Novel therapies and new targets required for developing more effective drugs for the treatment of AD patients are urgently needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50
Anisuzzaman AS, Uwada J, Masuoka T, Yoshiki H, Nishio M, Ikegaya Y, Takahashi N, Matsuki N, Fujibayashi Y, Yonekura Y, Momiyama T, Muramatsu I (2013) Novel contribution of cell surface and intracellular M1- muscarinic acetylcholine receptors to synaptic plasticity in hippocampus. J Neurochem 126(3):360–371
Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (2005) Memantine blocks alpha7∗ nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312:1195–1205
Atri A et al (2013a) Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5:6
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D (2013b) Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5:6
Bakchine S, Loft H (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13:97–107
Beal MF (1992) Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6:3338–3344
Benowitz NL, Kuyt F, Jacob P 3rd, Jones RT, Osman AL (1983) Cotinine disposition and effects. Clin Pharmacol Ther 34:604–611
Berger-Sweeney J (2003) The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neurosci Biobehav Rev 27:401–411
Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev (1):CD005593
Bowman ER, Mc KH Jr (1962) Studies on the metabolism of (−)-cotinine in the human. J Pharmacol Exp Ther 135:306–311
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 3:186–191
Bruel-Jungerman E, Lucassen PJ, Francis F (2011) Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res 221:379–388
Buisson B, Bertrand D (1998) Open-channel blockers at the human alpha4beta2neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555–563
Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs 17:641–652
Collina S, Gaggeri R, Marra A, Bassi A, Negrinotti S, Negri F, Rossi D (2013) Sigma receptor modulators: a patent review. Expert Opin Ther Pat 23:597–613
Coyle J, Kershaw P (2001) Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease. Biol Psychiatry 49:289–299
Cummings J et al (2014) Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther 6(4):37
Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I (2006) Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60:110–118
Dementia Fact Sheet No 362. http://who.int/mediacentre/factsheets/fs362/en/
Dinamarca MC, Rios JA, Inestrosa NC (2012) Postsynaptic receptors for amyloidbetaoligomers as mediators of neuronal damage in Alzheimer’s disease. Front Physiol 3:464
Drever BD, Riedel G, Platt B (2011) The cholinergic system and hippocampal plasticity. Behav Brain Res 221:505–514
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, Dekosky ST, Gauthier S, Selkoe D, Baterman R et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lacet Neurol 13:614–629
Echeverria V, Zeitlin R (2012) Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci Ther 18:517–523
Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, Mamcarz M, Wang L, Sattelle DB, Kirschner DA, Mori T, Leblanc RM, Prabhakar R, Arendash GW (2011) Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer’s disease mice. J Alzheimers Dis 24:817–835
Farlow M, Gracon S, Hershey L, Lewis SC, DolanUreno J (1992) A controlled trial of tacrine in Alzheimer disease. J Am Med Assoc 268:2523–2529
Farrimond LE, Roberts E, McShane R (2012) Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open 2. https://doi.org/10.1136/bmjopen-2012-000917
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphiconsensus study. Lancet 366:2112–2117
Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease. Neurotherapeutics 5:433–442
Fisher A (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem 120(Suppl. 1):22–33
Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z (2002) AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease. J Mol Neurosci 19:145–153
Gilling KE, Jatzke C, Hechenberger M, Parsons CG (2009) Potency, voltage dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Neuropharmacology 56:866–875
Godyn J, Jonczyk J, Panec D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68:127–138
Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer’s disease. Therapy and prevention strategies. Annu Rev Med 68:413–430
Hellstrom-Lindahl E, Moore H, Nordberg A (2000) Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74:777–784
Hellweg R, Wirth Y, Janetzky W, Hartmann S (2012) Efficacy of memantine in delaying clinical worsening in Alzheimer’s disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J GeriatrPsychiatry 27:651–656
Hernandez CM, Dineley KT (2012) Alpha7 nicotinic acetylcholine receptors in Alzheimer’s disease: neuroprotective, neurotrophic or both? Curr Drug Targets 13:613–622
Hippius H, Neundorfer G (2003) The discovery of Alzheimer’s disease. Dialogues Clin Neurosci 5:101–108
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O’Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366:893–903
Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST (2009) Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66:646–651
Jia JY, Zhao QH, Liu Y, Gui YZ, Liu GY, Zhu DY, Yu C, Hong Z (2013) Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine a, for the treatment of Alzheimer’s disease. Acta Pharmacol Sin 34(7):976–982
Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541–13546
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. BMJ 322:1447–1451
Klugman A, Naughton DP, Isaac M, Shah I, Petroczi A, Tabet N (2012) Antioxidant enzymatic activities in Alzheimer’s disease: the relationship to acetylcholinesterase inhibitors. J Alzheimers Dis 30:467–474
Kurz A, Perneczky R (2011) Novel insights for the treatment of Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 35(2):373–379
Lahmy V, Meunier J, Malmstrom S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T (2013) Blockade of tau hyperphosphorylation and abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology 38(9):1706–1723
Lee RH, Tseng TY, Wu CY, Chen PY, Chen MF, Kuo JS, Lee TJ (2012) Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries. PLoS One 7:40326
Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidli H, Appel-Dingemanse S (2008) Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 83:106–114
Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607
Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK (2010) Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci 40:135–137
Maskell PD, Speder P, Newberry NR, Bermudez I (2003) Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl- D-aspartate receptors. Br J Pharmacol 140:1313–1319
McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev:CD003154
Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A, LaFerla FM (2011) Loss of muscarinic M1 receptor exacerbates Alzheimer’s disease-like pathology and cognitive decline. Am J Pathol 179:980–991
Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK (2012) Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40. Eur J Pharmacol 692:38e45
Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C (1999) Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 13:20–25
Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E (2013) A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer’s disease. Br J Clin Pharmacol 75:1231–1239
Motawaj M, Burban A, Davenas E, Arrang JM (2011) Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer’s disease. J Pharmacol Exp Ther 336:479–487
Mousavi M, Hellstrom-Lindahl E (2009) Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 54:237–244
Muayqil T, Camicioli R (2012) Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementias. Dement Geriatr Cogn Dis Extra 2:546–572
Nakaya K, Nakagawasai O, Arai Y, Onogi H, Sato A, Niijima F, Tan-No K, Tadano T (2011) Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res 218:165–173
Ni R, Marutle A, Nordberg A (2013) Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer’s disease brain. J Alzheimers Dis 33:841–851
Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH (2000) The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 48:913–918
Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205–212
O’Brien J, Eagger S, Levy R (1991) Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer’s disease. Age Ageing 20:121–131
Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V (2002) Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 23(Suppl. 2):S95–S96
Parri RH, Dineley TK (2010) Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 7:27–39
Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. http://dx.doi.org/07/s12640-013-9398-z
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704–715
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group (2008a) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83–89
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008b) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83–89
Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, Konig G (2012) EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099–1110
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS (2011) A phase II trial of huperzine a in mild to moderate Alzheimer disease. Neurology 76:1389–1394
Ramirez-Bermudez J (2012) Alzheimer’s disease: critical notes on the history of a medical concept. Arch Med Res 43(8):595–599
Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306:81–84
Rammes G, Danysz W, Parsons CG (2008) Pharmacodynamics of memantine: an update. Curr Neuropharmacol 6:55–78
Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, Daniels JS, Jones CK, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Wood MR (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett 21:2697–2701
Revett TJ, Baker GB, Jhamandas J, Kar S (2013a) Glutamate system, amyloid peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38:6–23
Revett TJ, Baker GB, Jhamandas J, Kar S (2013b) Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38:6–23
Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I (2007) Domain specific improvement of cognition on memantine in patients with Alzheimer’s disease treated with rivastigmine. Dement Geriatr Cogn Disord 23:301–306
Rogers SL, Doody RS, Pratt RD, Ieni JR (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10:195–203
Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm 113:1625–1644
Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991–998
Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F (2006) Treatment of Alzheimer’s disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 127(2):148–157
Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, Nemeroff CB (1990) Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci U S A 87:2452–2455
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324
Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry 28:1109–1124
Toyohara J, Hashimoto K (2010) Alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer’s disease. Open Med Chem J 4:37–56
Wallace TL, Bertrand D (2013) Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 85(12):1713–1720
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 271:992–998
Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69:S14–S22
Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 97:1–13
Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine a: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173–183
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Revi, M. (2020). Alzheimer’s Disease Therapeutic Approaches. In: Vlamos, P. (eds) GeNeDis 2018. Advances in Experimental Medicine and Biology, vol 1195. Springer, Cham. https://doi.org/10.1007/978-3-030-32633-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-32633-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32632-6
Online ISBN: 978-3-030-32633-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)